Table 1.

Baseline characteristics of patients who received chemotherapy

XELOX + BV/XELOX	42/31
Median age (range)	64 (31–84)
Male/female	35/38
ECOG PS 0/1/2	61/10/2
Primary tumor colon/rectum	37/36
Stage II/III/IV	3/25/45
Oxaliplatin	851±228.9 mg/m2

Abbreviations: BV, bevacizumab; ECOG PS, Eastern Cooperative Oncology Group performance status; XELOX, capecitabine plus oxaliplatin.